Clearpoint Neuro Valuation
| CLPT Stock | USD 14.11 0.65 4.83% |
At this time, the firm appears to be undervalued. Clearpoint Neuro shows a prevailing Real Value of $17.2 per share. The current price of the firm is $14.11. Our model approximates the value of Clearpoint Neuro from analyzing the firm fundamentals such as profit margin of (0.67) %, and Return On Equity of -1.03 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Clearpoint Neuro's valuation include:
Price Book 25.2619 | Enterprise Value | Enterprise Value Ebitda (7.07) | Price Sales 11.6629 | Enterprise Value Revenue 11.6082 |
Undervalued
Today
Please note that Clearpoint Neuro's price fluctuation is not too volatile at this time. Calculation of the real value of Clearpoint Neuro is based on 3 months time horizon. Increasing Clearpoint Neuro's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Clearpoint Neuro's intrinsic value may or may not be the same as its current market price of 14.11, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 14.11 | Real 17.2 | Target 29.0 | Hype 13.9 |
The intrinsic value of Clearpoint Neuro's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Clearpoint Neuro's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Clearpoint Neuro helps investors to forecast how Clearpoint stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Clearpoint Neuro more accurately as focusing exclusively on Clearpoint Neuro's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Clearpoint Neuro's intrinsic value based on its ongoing forecasts of Clearpoint Neuro's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Clearpoint Neuro's closest peers.
Clearpoint Neuro Cash |
|
Clearpoint Revenue by Product
Clearpoint Neuro Total Value Analysis
Clearpoint Neuro is currently projected to have valuation of 398.53 M with market capitalization of 400.41 M, debt of 3.57 M, and cash on hands of 45.14 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Clearpoint Neuro fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
398.53 M | 400.41 M | 3.57 M | 45.14 M |
Clearpoint Neuro Investor Information
About 42.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 0.83. Clearpoint Neuro last dividend was issued on the 27th of July 2016. The entity had 1:40 split on the 27th of July 2016. Based on the analysis of Clearpoint Neuro's profitability, liquidity, and operating efficiency, Clearpoint Neuro may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter.Clearpoint Neuro Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Clearpoint Neuro has an asset utilization ratio of 80.1 percent. This implies that the Company is making $0.8 for each dollar of assets. An increasing asset utilization means that Clearpoint Neuro is more efficient with each dollar of assets it utilizes for everyday operations.Clearpoint Neuro Profitability Analysis
Considering Clearpoint Neuro's profitability and operating efficiency indicators, Clearpoint Neuro may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in March. Profitability indicators assess Clearpoint Neuro's ability to earn profits and add value for shareholders.Net Loss | First Reported 2011-06-30 | Previous Quarter -5.8 M | Current Value -5.9 M | Quarterly Volatility 1.8 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.74 | 0.7 |
|
|
For Clearpoint Neuro profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Clearpoint Neuro to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Clearpoint Neuro utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Clearpoint Neuro's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Clearpoint Neuro over time as well as its relative position and ranking within its peers.
Clearpoint Neuro Earnings per Share Projection vs Actual
By analyzing Clearpoint Neuro's earnings estimates, investors can diagnose different trends across Clearpoint Neuro's analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for Clearpoint Neuro is based on EPS before non-recurring items and includes expenses related to employee stock options.Clearpoint Neuro Ownership Allocation
Clearpoint Neuro holds a total of 29.75 Million outstanding shares. 30% of Clearpoint Neuro outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Clearpoint Neuro Profitability Analysis
The company reported the previous year's revenue of 31.39 M. Net Loss for the year was (18.91 M) with profit before overhead, payroll, taxes, and interest of 21.05 M.About Clearpoint Neuro Valuation
The stock valuation mechanism determines Clearpoint Neuro's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Clearpoint Neuro based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Clearpoint Neuro. We calculate exposure to Clearpoint Neuro's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Clearpoint Neuro's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 22 M | 23.1 M | |
| Pretax Profit Margin | (0.54) | (0.57) | |
| Operating Profit Margin | (0.57) | (0.59) | |
| Net Loss | (0.54) | (0.57) | |
| Gross Profit Margin | 0.70 | 0.74 |
Clearpoint Neuro Current Valuation Indicators
Clearpoint Neuro's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Clearpoint Neuro's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Clearpoint Neuro, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Clearpoint Neuro's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Clearpoint Neuro's worth.Additional Tools for Clearpoint Stock Analysis
When running Clearpoint Neuro's price analysis, check to measure Clearpoint Neuro's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Clearpoint Neuro is operating at the current time. Most of Clearpoint Neuro's value examination focuses on studying past and present price action to predict the probability of Clearpoint Neuro's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Clearpoint Neuro's price. Additionally, you may evaluate how the addition of Clearpoint Neuro to your portfolios can decrease your overall portfolio volatility.